CH
CARM

CVI Holdings’s Carisma Therapeutics CARM Stock Holding History

CVI Holdings’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-236,899
Closed -$5.54M – 39
2019
Q3 		$5.54M Sell
236,899
-168,745
-42% -$3.95M 12.44% 3
2019
Q2 		$12.2M Buy
+405,644
New +$12.1M 14.05% 2

Other funds holding CARM

TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

CVI Holdings's CARM Position: Q4 2019 in Review

CVI Holdings sold out of Carisma Therapeutics (CARM) in Q4 2019, closing a stake of 236,899 shares — an estimated $5.54M sold.

CVI Holdings first reported a position in CARM in Q2 2019 and held it in 2 quarters. The position peaked at $12.2M in Q2 2019. 46 funds tracked by Wall St. Rank hold CARM as of Q4 2019.

  • CVI Holdings reported no remaining Carisma Therapeutics position as of Q4 2019 after selling out during the quarter.
  • CVI Holdings sold 236,899 Carisma Therapeutics shares in Q4 2019, an estimated $5.54M.
  • CVI Holdings first reported a position in Carisma Therapeutics in Q2 2019 and held it in 2 quarters.
  • CVI Holdings's Carisma Therapeutics position peaked at $12.2M in Q2 2019.
  • 46 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2019.

Based on CVI Holdings's 13F filing for Q4 2019, filed 14 Feb 2020.